Slide 1

543 / 1631

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in
first-line treatment of indolent NHL or MCL: the BRIGHT study.
• Primary Objective: Determine if BR is non-inferior (CR rate) to standard tx (R-
CHOP or R-CVP)
• Indolent or
Mantle Cell
• Stage II+
• Untreated
R
A
N
D
O
M
I
Z
E
(N=447)
Bendamustine 90 mg/m2 Days 1-2
Rituximab 375 mg/m2 Day 1
CHOP-Rituximab (R-CHOP)
(Standard Dosing)
CVP-Rituximab (R-CVP)
(Standard Dosing)
-or-
(N=224)
(N=223)